VPHM's Cinryze is approved for prophylaxis of HAE.
That's just one drug, though. So, presumably the prophylaxis HAE market isn't exactly crowded and could use additional treatments, particularly if DX-2930 ends up having the potential advantages genisi cited in #msg-87316214 .
It's certainly going to be a few years before we find out these answers on DX-2930 but if it does pan out, I imagine shares will end proving to be a nice risk-reward at this level. I'm at least putting DYAX on my watchlist pending some more DD on their financial shape.
Market Data 
Markets 
AI
